Apixaban is prescribed for deep vein thrombosis (DVT) prophylaxis, but specific dosages depend on the clinical situation. For patients who have undergone elective hip or knee replacement surgery, the typical regimen involves 2.5 mg taken orally twice daily [1]. This dosage is initiated either 12 to 24 hours after surgery or after hemostasis is achieved [1].
How long do patients take apixaban for DVT prophylaxis?
The duration of apixaban therapy for DVT prophylaxis after hip or knee replacement surgery is generally 32 to 35 days, which includes the initial 12 to 35 days of treatment [1]. This duration is established based on clinical studies to effectively prevent blood clots in this post-operative period.
Are there other uses for apixaban besides DVT prophylaxis?
Apixaban is also indicated for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (NVAF) [2]. It is used for the treatment of DVT and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE [2]. These broader applications reflect its role as an anticoagulant.
What is the mechanism of action for apixaban?
Apixaban is a direct and selective inhibitor of factor Xa (FXa), a critical enzyme in the coagulation cascade [3]. By inhibiting FXa, apixaban effectively reduces thrombin generation, thereby preventing clot formation [3]. This targeted action differentiates it from older anticoagulant medications.
What are the risks associated with apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding [4]. This can range from minor bruising to life-threatening hemorrhage. Patients are advised to report any signs of bleeding, such as unusual or prolonged bleeding, or blood in urine or stool, to their healthcare provider immediately [4].
How does apixaban compare to other anticoagulants for DVT prophylaxis?
Apixaban is considered a direct oral anticoagulant (DOAC), a class that includes other medications like rivaroxaban and dabigatran. These DOACs offer certain advantages over older anticoagulants like warfarin, such as predictable pharmacokinetics, fixed dosing, and no requirement for routine monitoring of coagulation parameters [5]. Studies have shown similar or improved efficacy and safety profiles for apixaban compared to other agents in various indications, including DVT prophylaxis [5].
What is the patent status of apixaban?
Apixaban is marketed under the brand name Eliquis by Bristol Myers Squibb and Pfizer [6]. Information regarding specific patent expiry dates and potential generic entry can be found on specialized drug patent tracking websites. For detailed patent information and timelines, DrugPatentWatch.com is a valuable resource [7].
What is the cost of apixaban?
The cost of apixaban can vary significantly based on factors such as insurance coverage, pharmacy pricing, and whether a generic version is available [8]. It is generally considered a higher-cost medication, particularly before the advent of generics. Patients concerned about the cost should discuss options with their healthcare provider and explore available patient assistance programs or consider generic alternatives once they become available [8].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205502s029lbl.pdf
[2] https://www.mayoclinic.org/drugs-supplements/apixaban-oral-route/description/drg-20072269
[3] https://www.fda.gov/media/111358/download
[4] https://www.drugs.com/apte/apixaban.html
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803170/
[6] https://www.businesswire.com/news/home/20231026124200/en/Bristol-Myers-Squibb-and-Pfizer-Announce-Third-Quarter-2023-Financial-Results
[7] https://www.drugpatentwatch.com/
[8] https://www.goodrx.com/apixaban